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Binding properties of a selective tritiated vasopressin V2 recep- ron [1]. The V2 receptor belongs to the seven-transmem-
tor antagonist, [3H]-SR 121463. brane, G-protein–coupled receptor family, and its intra-
Background. [3H]-SR 121463 is the first radiolabeled selec- cellular signaling pathway involves a Gs/adenylyl cy-tive nonpeptide vasopressin V2 receptor antagonist ligand that clase-stimulating system that induces cAMP formation.has been reported to date. In the present work, we studied the
The renal V2 receptor has been cloned in different spe-binding properties of [3H]-SR 121463 for renal V2 receptors
from animal and human origins. cies, including rat, pig, bovine, and human, and shares a
Methods. Binding studies were performed with [3H]-SR 121463 high sequence homology [2–5]. Despite this fact, marked
in Chinese hamster ovary (CHO) cells transfected with the species differences have been reported in the pharmacol-human V2 receptor and in various kidney preparations express- ogy of this receptor [6]. The V2 receptor is present ining the native V2 receptors (rat, rabbit, dog, pig, monkey, and
greatest amounts in the kidney, but recently, polymerasehuman). Autoradiographies were performed in rat and human
kidney sections. chain reaction studies revealed that V2 receptor mRNA
Results. [3H]-SR 121463 binding to CHO cells stably trans- is also present in other tissues or cells such as the brain,
fected with the cloned human renal V2 receptor was specific, the liver, and the lung and in small cell lung cancerhighly stable, time dependent, saturable, and reversible. A single
(SCLC) and corticotroph tumors [7–11]. Moreover, thepopulation of high-affinity binding sites was identified (Kd 5
existence of functional extrarenal V2 receptors involved0.94 6 0.34 nmol/L, Bmax 5 9876 6 317 fmol/mg protein). Of
note, [3H]-SR 121463 revealed a higher number (about 40%) in clotting factor release (factor VIII and von Willebrand
of V2 sites than [3H]-AVP in the same preparation. Displace- factor) has been clearly demonstrated; however, their
ment of [3H]-SR 121463 binding by reference peptide and non- exact localization remains to be determined [12–14].peptide vasopressin/oxytocin compounds exhibited a typical
Highly selective AVP V2 receptor ligands with highAVP V2 profile. [3H]-SR 121463 also displayed a high affinity
for native V2 receptors in several kidney preparations from affinity and stability constitute major tools for investigat-
rat, pig, dog, rabbit, bovine, monkey, and human. The autoradio- ing the localization/mapping and the pharmacological
graphic experiments using rat and human kidney sections functions of these receptors. From a therapeutic point
showed intense labeling in the medullopapillary region and
of view, AVP V2 receptor-specific antagonists able tolower intensity in the cortex, consistent with a main localization
block the action of AVP at the level of the renal collect-of V2 receptors on collecting tubules.
Conclusion. [3H]-SR 121463 is a useful ligand for the specific ing duct specifically promote water excretion. Such
labeling of animal and human V2 receptors and could be a “aquaretic” agents could be of high interest for the treat-
suitable probe for the search and in situ localization of V2 sites. ment of several water-retaining disorders such as syn-
drome of inappropriate antidiuretic hormone secretion
(SIADH), hyponatremia, liver cirrhosis, certain stages
Vasopressin (AVP) plays a major role as an antidiure- of congestive heart failure, and hypertension [15, 16].
tic hormone regulating water and solute excretion by the Extensive work in the design of peptide ligands with
kidney through specific interaction with renal V2 recep- high affinity and specificity for animal and human AVP/
tors present in the collecting duct of the mammalian neph- oxytocin (OT) receptors has been carried out [17, 18],
leading to the discovery of selective V1a [19–23] and OT
[24] receptor ligands. Although a peptide-radioiodinatedKey words: kidney, antidiuretic hormone, arginine vasopressin, homeo-
stasis, water regulation, ligand. ligand for the AVP V2 receptor was recently reported,
it displays high affinity for rat and human AVP V2 and V1aReceived for publication December 10, 1999
receptors and, therefore, cannot easily be used to spe-and in revised form March 15, 2000
Accepted for publication May 12, 2000 cifically label V2 receptors [25]. Over the past decade,
several orally active nonpeptide AVP receptor antago-Ó 2000 by the International Society of Nephrology
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nists have been reported [reviewed in 26]. One of them,
SR 121463 (1-[4-(N-tert-butylcarbamoyl)-2-methoxyben-
zene sulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy-
cyclohexane)] indoline-2-one, cis-isomer), has been shown
to be a potent and selective AVP V2 receptor antagonist
[27]. This highly stable molecule displays a high selective
affinity for V2 receptors from several species, including
humans, and exhibits powerful intravenous and oral
aquaretic effects [27]. Moreover, SR 121463 inhibits AVP-
evoked cAMP formation in human kidney membranes
and reverses extrarenal V2 receptor agonism of dDAVP-
induced release of homeostasis factors in dogs [14].
Thus, SR 121463 represents an interesting probe for
the characterization and localization of V2 receptors in
animals and humans. This compound has been tritiated
and used in our current study for the characterization of
renal V2 receptors. The present work reports the binding
Fig. 1. Chemical structure of [3H]-SR 121463. The * indicates the posi-properties of [3H]-SR 121463 to membranes from Chi-
tion of tritium. (Reproduced from the Journal of Clinical Investigation
nese hamster ovary (CHO) cells stably transfected with [27], with permission from the American Society for Clinical Investigation.)
the cloned human renal V2 receptor, mainly in terms of
kinetics, equilibrium-binding parameters, and specificity.
We used a wide number of peptide and nonpeptide refer-
O-Me-Tyr2,Arg8]-AVP were obtained from Sigma Chemi-ence antagonists to characterize [3H]-SR 121463 binding
cal Co. (L’Isle d’Abeau, France). [Thr4,Gly7]-OT, [Phe2,further, and a close comparison was established with
lle3,Orn8]-AVP, d(CH2)5,Tyr(Me)2,Thr4,Tyr-NH2-OVT,[pGlu4,binding results obtained using the natural tritiated hor-
Cystine8]-AVP4–9, d(CH2)5Tyr(Me)AVP, [d(CH2)5,D-lle2,mone, [3H]-AVP. In addition, we used [3H]-SR 121463
lle4,Arg8]-AVP, [d(CH2)5,D-Phe2,lle4,Ala9-NH2]-AVP werefor labeling native V2 receptors in different renal prepa-
obtained from Peninsula Laboratories (Orsay, France). Des-rations from animal (that is, rat, rabbit, pig, dog, monkey,
Gly-[Pha1,D-Tyr(Et)2-Lys6-Arg8]-AVP, SKF-105494 [o-ethyl-and bovine) and human origin. Finally, we performed
D-Tyr1-Phe2-val3-Asn4-[1-(carboxymethyl)cyclohexyl]5-L-autoradiographic experiments with [3H]-SR 121463 on
norvalyl6-Arg7-D-ArgNH28, cyclic (5!1)] was a generousrat and human kidney sections for in situ mapping of
gift from Dr. L. Bankir and Dr. Kinter. SKF-101926AVP V2 receptors. Our results show that [3H]-SR 121463
([d(CH2)5,D-Tyr(Et)2,Val4,Arg8, des-Gly9]-AVP) was ob-binds with high affinity to renal V2 receptors from various
tained from Bachem (Voisin Le Bretonneux, France).species, including humans, and is a suitable probe for
[Des-Glycinamide9, d(CH2)5, O-Me-Tyr2,Thr4,Orn8]-vaso-the selective localization of AVP V2 receptors.
tocin was obtained from Saxon/Interchim (Montluc¸on,
France). Dulbecco’s modified Eagle medium (DMEM)
METHODS and phosphate-buffered saline (PBS) were from Boeh-
Chemicals ringer Mannheim (Meylan, France). All other cell culture
reagents were from GIBCO (Life Technologies, GIBCOReference nonpeptide AVP receptor antagonists, SR
BRL, Cergy Pontoise, France). Ethylenediaminetetraace-121463 (1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzene
tic acid (EDTA), Tris, and DMSO were obtained fromsulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)cyclo-
Merck-Clevenot (Nogent sur Marne, France). All otherhexane]indol-2-one, monophosphate salt, molecular weight
chemicals were from Prolabo (Paris, France).759.82-SR 121463B-) [27], SR 49059 [28], OPC-31260 [29],
OPC-21268 [30], YM-087 [31], and VPA-985 [32] were syn-
Biological materialthesized at Sanofi-Synthelabo. The purity, measured by high-
Tissue samples from human kidneys were collected inpressure liquid chromatography, thin layer chromatography,
conformity with the national ethical rules and were ob-and elemental analysis, was more than 98%. They were
tained at the time of nephrectomy from patients aged 40dissolved in dimethylsulfoxide (DMSO) at 1022 mol/L and
to 60 years. Immediately after excision, tissues were dis-then diluted in the appropriate test solvent. [3H]-SR 121463
sected, and reno-medullary samples were either frozen at(47.5 Ci/mmol; Fig. 1) and [3H]-AVP (30 to 70 Ci/mmol)
2408C in isopentane and further stored at 2808C for auto-were purchased from New England Nuclear, Life Science
radiographic experiments or crude plasma membranesProducts (Les Ulis, France). AVP, dDAVP (1-desamino-
were prepared for binding studies. This project was ap-[D-Arg8]-AVP), [Lys8]-AVP, d(D-3Pal)AVP (deamino1
(D-3-(Pyridyl)Ala2, Arg(8)-AVP, OT, [deamino-Pen1, proved by the human subject ethical review committees
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of our institutions and was carried out in collaboration similar operating conditions using [3H]-AVP as a ligand
(3 nmol/L). In this case, the nonspecific binding waswith Hopital Lapeyronie (Montpellier, France). Bovine
kidneys were from a local slaughterhouse; male New measured in the presence of 10 mmol/L unlabeled AVP.
Data for equilibrium binding [apparent equilibriumSprague-Dawley rats (250 to 350 g) and male New
Zealand rabbits (2.5 to 3 kg) were purchased from Iffa- dissociation constant (Kd), maximum binding density
(Bmax)], competition experiments [IC50, Hill coefficientCredo (Lyon, France). Bred mongrel dogs (16 to 22 kg)
and pigs were from les Souches and Cegan Ltd. (France), (nH)], and kinetic constants [observed association rate
constant (kobs), apparent dissociation rate constant (k21)respectively. Bred Cynomolgus monkeys, Macaca fascic-
ularis (3 to 5 kg), were supplied by CRP Ltd. (Mauritius, and apparent association rate constant k11 5 (kobs 2
k21)/[L] with [L] equal to the radioligand concentration]France).
were calculated using an interactive nonlinear regression
Cell culture and preparations of cell homogenates program [38]. The IC50 value was defined as the concen-
tration of inhibitor required to obtain 50% inhibition ofCHO-DHFR2 cells (DXB11) were transfected with an
expression vector derived from plasmid 7055 containing the specific binding. Inhibition constant (Ki) values were
calculated from the IC50 values using the Cheng andthe cDNA encoding the human V2 receptor. Stably trans-
formed cell lines were isolated as described earlier [33, Prusoff equation [39]. For peptide compounds, an appar-
ent IC50 value was determined considering the fraction34]. They were grown in 10 mmol/L HEPES, pH 7.4,
minimal essential medium (MEM) supplemented with of displaceable sites by these peptides.
5% fetal calf serum and 8 g/L sodium bicarbonate and
Autoradiography300 mg/mL geneticin at 378C in a humidified atmosphere
containing 5% CO2. Wild-type CHO cells were routinely Human kidney samples dissected in the medullary
papillary region and whole rat kidney were used. Serialgrown in a similar culture medium. Cells, grown to con-
fluence, were collected by scraping, and crude mem- sections (15 mm thick) from frozen rat and human kid-
neys were mounted onto gelatin chrome-alum slides,branes were prepared by homogenization of cells as pre-
viously described [35]. Culture medium were removed rinsed to eliminate endogenous AVP, and incubated with
1.5 nmol/L [3H]-SR 121463 with (nonspecific binding) orevery other day, and cells were subcultured by treatment
with 0.05% trypsin, 0.02% EDTA. without (total binding) 1 mmol/L unlabeled SR 121463 as
described previously [27]. After incubation, the sections
Membrane preparations were washed three times for 10 minutes each in ice-cold
binding buffer, dipped briefly in distilled water, and driedReno-medullary membranes from rat, rabbit, dog, pig,
bovine, monkey, and humans were prepared according under a stream of cold air. Rinsed labeled sections were
placed on a phosphor-imaging plate (Fuji, Tokyo, Japan)to Stassen et al [36] and were stored as aliquots in liquid
nitrogen until use at a final concentration of about 10 mg for four days and further analyzed with a Bio-Image
Analyzer (BAS 5000; Fuji) as already described [40].protein/mL. The protein concentration was determined
by the method of Bradford using bovine serum albumin
as a standard [37].
RESULTS
Binding of [3H]-SR 121463 to human V2 receptorsAVP V2 binding assays
expressed in CHO cellsChinese hamster ovary membranes expressing the hu-
man V2 receptors or reno-medullary preparations from Tissue-binding linearity. Preliminary experiments have
shown that [3H]-121463–specific binding to crude cellrat, rabbit, dog, pig, bovine, monkey, and humans were
incubated in a 50 mmol/L Tris-HCl buffer, pH 8.1, con- homogenates was linear with increasing protein concen-
tration up to 30 mg/tube (that is, 150 mg/mL). Nonspecifictaining 2 mmol/L MgCl2, 1 mmol/L EDTA, 0.1% bovine
serum albumin (BSA), 0.1% bacitracin, and [3H]-SR binding determined in the presence of 1 mmol/L unla-
beled SR 121463 was very low and ranged between 1121463 (0.03 to 10 nmol/L for saturation experiments or
2 nmol/L for kinetic and competition studies), and in- and 5% of the total binding (data not shown).
Kinetics binding studies. As shown in Figure 2, [3H]-creasing amounts of the tested compound. The reaction
was started by the addition of membranes (30 mg/assay SR 121463–specific binding to V2 receptors expressed in
CHO cell membranes was rapid (t1/2 5 5 6 3 min, N 5for CHO and 100 to 200 mg/assay for native renal mem-
branes) and incubation for 45 minutes at 258C (except 3) and time-dependent and reached equilibrium in about
20 minutes at 258C (kobs 5 0.033 6 0010 min21). Thein association-dissociation studies) and was then stopped
by filtration through Whatman GF/B filters as previously apparent equilibrium binding level remained highly sta-
ble and unchanged during the three-hour observationdescribed [27]. Nonspecific binding was determined in
the presence of 1 mmol/L SR 121463. Competition and period. Dissociation of the [3H]-SR 121463 receptor com-
plex, initiated after 45 minutes of incubation by the addi-saturation-binding experiments were conducted under
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from Scatchard plot and kinetics experiments. The selec-
tive V2 receptor antagonist VPA-985 and the two non-
peptide V2/V1a receptor antagonists OPC-31260 and YM-
087 displaced bound [3H]-SR 121463 with nanomolar Ki
values (8.8 6 0.7 and 0.67 6 0.05 nmol/L, respectively)
in agreement with data previously reported in various
animal and human AVP V2 preparations [27, 32]. As ex-
pected, the selective nonpeptide V1a receptor antagonist
SR 49059 exhibited low potency in displacing [3H]-SR
121463. Displacement curves obtained in each case gave
linear Hill plots and pseudo Hill coefficient (nH) of about
one (data not shown).
It is important to note that with these nonpeptide li-
gands, we observed total displacement of [3H]-SR 121463
bound to membranes, whereas with peptide compounds
Fig. 2. Time–course of association (d) and dissociation (s) of [3H]- such as AVP, dDAVP (a V2 receptor agonist), SKF com-SR 121463 to membranes of Chinese hamster ovary (CHO) cells ex-
pounds (V2 receptor antagonists), and d(CH2)5Tyr(Me)pressing the human renal arginine vasopressin (AVP) V2 receptors.
Incubations were carried out as described in the Methods section in AVP (a V1a receptor antagonist), even at high concentra-
the presence of 2 nmol/L [3H]-SR 121463 for various periods of time. tions we observed only partial displacement of [3H]-SRThe arrow indicates time (45 min) at which unlabeled SR 121463
121463 bound to our preparation (Fig. 4B and Table 1).(1 mmol/L) was added to initiate the dissociation process. The results
represent data from a typical experiment performed in duplicate and Computer analysis of the data obtained with peptide
repeated three times without noticeable modifications. compounds indicated that the binding was best fitted to
a two-site model: one site (about 60%) displaceable by
AVP (and peptide analogues) and exhibiting the ex-
pected V2 profile according to the rank order of affinitytion of 1 mmol/L unlabeled SR 121463 (Fig. 2), occurred
slowly with an apparent dissociation constant (k21) value found for the reference compounds studied (Table 1)
and a second site (about 40%) totally insensitive to AVPof 0.0066 6 0.0012 min21. Two and a half hours after initi-
ation of the dissociation process, 30% of remaining spe- and to other agonist or antagonist peptide compounds
(whatever their AVP/oxytocin profile) and only displace-cific binding to membranes was still observed indicating
slow dissociation. From kinetics experiments, an approx- able by nonpeptide AVP receptor antagonists according
to a V2 rank order of potency. Interestingly, the proportionimate calculated Kd value of 0.4 nmol/L was obtained.
Saturation-binding studies. Saturation experiments per- of “AVP-insensitive” sites (near 40%) was in good agree-
ment with Bmax values obtained from Scatchard plots usingformed in the presence of increasing concentrations of
[3H]-SR 121463 showed that the specific binding was [3H]-SR 121463 and [3H]-AVP as ligands (5524 6 887 vs.
9876 6 317 fmol/mg protein; Fig. 3).saturable (Fig. 3A). Scatchard analysis of these data gave
a linear plot consistent with the presence of a single Specificity of [3H]-SR 121463 binding. Despite the
highly selective profile previously reported for SR 121463class of high-affinity binding sites characterized by an
apparent Kd of 0.94 6 0.34 nmol/L and a maximal binding [27], one could speculate that the CHO cell line used
might express other native binding sites recognized bycapacity (Bmax) of 9876 6 317 fmol/mg protein (that is,
approximately 500,000 sites/cell, N 5 3). Saturation bind- SR 121463 and unrelated to AVP receptors. This hypoth-
esis can be discarded, since no specific binding could being experiments, performed under similar experimental
conditions, with the natural tritiated ligand [3H]-AVP detected in membranes of untransfected CHO wild-type
cells when using [3H]-SR 121463 (data not shown). More-revealed a linear Scatchard plot with a nanomolar Kd
value (1.80 6 1.40 nmol/L)—similar to that of [3H]-SR over, additional binding experiments performed with
[3H]-SR 121463 (2 nmol/L) in CHO or ltK2 cell lines121463—and a significantly lower number of binding
sites (about 40%, Bmax 5 5524 6 897 fmol/mg protein) stably expressing human V1a, V1b, or oxytocin receptors
did not reveal any specific binding, in agreement withthan that obtained with [3H]-SR 121463 (Fig. 3B).
Competition-binding studies. The relative affinities of an extremely high specificity for the V2 receptor subtype
versus other AVP/oxytocin receptors. As expected, forseveral reference peptide or nonpeptide AVP/oxytocin
compounds were studied to characterize further the an antagonist radioligand able to recognize the different
states of a G-protein–coupled receptor, binding of [3H]-binding of [3H]-SR 121463 (Table 1 and Fig. 4). As shown
in Figure 4A, [3H]-SR 121463 binding to the human V2 SR 121463 was insensitive to guanylnucleotides (100
mmol/L GTP, GppNHp, GTPgs) and 140 mmol/L Na1receptor was inhibited in a dose-dependent manner by
unlabeled SR 121463, yielding a Ki value of 0.54 6 0.09 (data not shown), which are well-known conditions able
to promote the low-affinity state for the receptor.nmol/L (N 5 4), consistent with Kd values obtained both
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Fig. 3. Saturation of [3H]-SR 121463 (d) and
[3H]-AVP (j) specific binding to membranes
of CHO cells transfected with the human renal
AVP V2 receptors. (A) Saturation isotherms.
(B) Scatchard plots. Incubations were per-
formed for 45 minutes at 258C in the presence
of 10 mg protein/mL and increasing concen-
trations of [3H]-SR 121463 or [3H]-AVP as
described in the Methods section. Data are
means calculated from a typical experiment
performed in duplicate and repeated three
times without noticeable changes.
Table 1. Inhibition of [3H]-SR 121463 binding to CHO cells transfected with the human AVP V2 receptor by reference peptide and
nonpeptide AVP/OT compounds
% Sites displaced
Kd nmol/L at 1025 mol/L
Nonpeptide
SR 121463 0.5460.09 100
VPA-985 0.6160.21 100
YM-087 0.6560.05 100
OPC-31260 8.860.7 100
SR 49059 232648 100
OPC-21268 .10,000 3
Peptide
AVP 1266 63
dDAVP 51618 53
[Lys8]-AVP 104610 67
d(D-3Pal)AVP .10,000 14
OT .1,000 21
[Thr4,Gly7]-OT .10,000 6
POVT .10,000 6
d(CH2)5,Tyr(Me)2,Thr4,Tyr-NH2-OVT 990679 47
[Des-glycinamide9,d(CH2)51,O-Me-Tyr2,Thr4,Orn9]-vasotocin .10,000 9
[pGlu4,cystine8]-AVP 4-9 .10,000 3
d(CH2)5Tyr(Me)AVP 160666 58
[d(CH2)5,D-lle2,lle4,Arg8]-AVP 113621 65
[d(CH2)5,D-lle2,lle4,Ala9-NH2]-AVP 2266 67
des-Gly-[Pha1,D-Tyr(Et)2-Lys6-Arg8]-AVP 238642 62
[deamino-Pen1,O-Me-Tyr2,Arg8]-AVP 546665 58
SKF-105494 1.360.5 68
SKF-101926 4.862.5 65
Inhibition constants (Ki) were calculated according to the Cheng and Prusoff equation [39] as described in Methods section. Values are means 6 SD (N 5 3 to 6).
The % of site displaced at 1025 mol/L is indicated.
Fig. 4. Inhibition of [3H]-SR 121463-specific
binding to membranes of CHO cells express-
ing the human renal AVP V2 receptor by refer-
ence nonpeptide (A) and peptide (B) AVP/OT
compounds. Incubations were carried out in
the presence of 1.5 nmol/L [3H]-SR 121463 and
increasing concentrations of the compound to
be tested. Symbols in (A) for nonpeptide com-
pounds: (s) SR 121463; (d) YM-087; (h)
VPA 985; (j) OPC-31260; (.) SR 49059;
(,) OPC-21268. Symbols in (B) for peptide
compounds: (.) AVP; (s) dDAVP; (j)
d(CH2)5Tyr(Me)AVP; (d) SKF-101926; (h)
d(CH2)5,D-lle2,lle4,Arg8]-AVP. Data are the
means of a typical experiment performed in
duplicate and repeated several times without
noticeable changes.
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Table 2. Equilibrium binding parameters (Kd, Bmax) of likely corresponding to cortical collecting tubules from
[3H]-SR 121463 and [3H]-AVP for V2 receptors in various long-loop nephrons. This is consistent with the knowncrude animal and human kidney preparations
renal V2 receptor localization in the rat kidney [25]. Bind-
[3H]-SR 121463 [3H]-AVP ing in the medulla was more easily displaced by cold SR
Ki Bmax Ki Bmax 121463 than in the cortical region (Fig. 5D).
nmol/L fmol/mg protein nmol/L fmol/mg protein
Rat 1.5160.70 220636 0.6360.25 93650
Rabbit 0.9060.15 113622 0.85633 123642 DISCUSSION
Pig 0.4660.12 161631 0.7360.20 216616
The present study demonstrates that [3H]-SR 121463Dog 0.6560.16 151629 1.1160.65 109612
Monkey 0.7760.42 3196153 1.2060.20 129618 displays high and specific affinity for AVP V2 receptors
Bovine 0.8360.32 10386217 0.5660.14 6706324 from animal and human origin and constitutes a suitable
Human 0.5460.08 223619 1.3560.46 151657
probe for investigating these receptors, especially in com-
plex organs expressing mixed populations of AVP/OT
receptor subtypes.
Receptors for AVP and OT are widely distributed andBinding of [3H]-SR 121463 to V2 receptors from have been identified with various functions. However,various animal and human native kidney preparations
many pharmacological experiments and binding/auto-
Saturation binding experiments performed with [3H]- radiographic studies have been hampered or limited in
SR 121463 in membranes prepared from the medulla their interpretation by the lack of potent and highly
and the papillary area of the kidney from various species selective ligands for V1a, V1b, V2, and OT receptors. Selec-
(rat, rabbit, dog, bovine, monkey, and humans) demon- tive peptide and nonpeptide, tritiated or iodinated, V1a
strated an excellent affinity of [3H]-SR 121463 for V2 or OT ligands are currently available [17, 24], but up to
receptors (Kd value in the nanomolar range; Table 2). now, the design of peptide or nonpeptide radiolabeled
Whatever the species, [3H]-SR 121463 bound to a single ligands with high affinity and specificity for animal and
class of high-affinity binding sites and displayed a higher human AVP V2 receptors has been unsuccessful. Species
(or at least comparable) affinity than the natural hor- differences and a lack of selectivity are the major draw-
mone, [3H]-AVP, for these native V2 receptors. Interest- backs of the potent peptide AVP V2 compounds reported
ingly, we found similar binding affinity of [3H]-SR 121463 so far [6, 25, 41, 42]. Although attempts have been made
in CHO cells stably transfected with the human V2 recep- to label V2 receptors with [3H]-dDAVP [43], a well-
tor and in crude human kidney preparations (Kd values known peptide V2 agonist, recent data demonstrated
obtained from saturation experiments and Scatchard high affinity of this compound for human V1b receptors
analysis, 0.94 6 0.34 vs. 0.54 6 0.08 nmol/L, respectively). as well [44]. Another potent and selective V2 receptor
It is also important to note a marked heterogeneity in antagonist ligand, [3H]-desGly-NH29-d(CH2)5 [D-Ileu2,
the number of V2 sites found in the different studied Ileu4]-AVP, exhibited marked species difference and was
species (Bmax values ranged from 113 6 22 fmol/mg pro- a suitable ligand only for labeling rat V2 receptors [45]. In
tein in the rabbit to 1038 6 217 fmol/mg protein in bovine comparison, the nonpeptide AVP V2 receptor antagonist
renal membranes). Notably, compared with [3H]-AVP [3H]-SR 121463 binds with high affinity to V2 receptors
(a V1 and V2 ligand), [3H]-SR 121463 identified a similar in native kidney membrane preparations from rat, rabbit,
(rabbit, pig, and dog) or even higher (rat, monkey, and dog, pig, bovine, monkey, and human origin, with Kd
humans) number of binding sites according to the origin values similar to, or even higher than, those found for the
of the preparation (Table 2). natural hormone [3H]-AVP. The difference in receptor
number (Bmax values) observed between these various
Autoradiography experiments with [3H]-SR 121463 kidney preparations (obtained under similar operating
in rat and human kidney sections conditions) showed marked species heterogeneity in re-
Figure 5 shows autoradiograms obtained from human nal V2 receptor density as already described for the liver
and rat kidney sections incubated with [3H]-SR 121463 V1a receptors [46].
in the presence or absence of unlabeled SR 121463. A The present study provides a detailed characterization
dense labeling was observed in the medullopapillary por- of this new nonpeptide ligand by studying the binding
tion dissected from the human kidney, with lower label- properties of [3H]-SR 121463 to membranes from CHO
ing in the outer medulla/cortical extremity showing a cells stably transfected with the cloned human renal AVP
tubular pattern (Fig. 5A). In rat whole kidney sections, V2 receptor. [3H]-SR 121463 binding was specific, highly
specific binding was mainly seen in the inner/outer me- stable, time-dependent, saturable, and reversible, with
dulla and papilla corresponding to the main localization minimal nonspecific binding measured in the presence
of collecting ducts. Much less intense specific binding of 1 mmol/L unlabeled SR 121463 (less than 5%). Associ-
ation occurred rapidly (t1/2 about 5 min) to reach a re-was also detected in the cortical portion of the kidney
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Fig. 5. Labeling of AVP V2 receptors with
[3H]-SR 121463 in human (A and B) and rat
(C and D) kidney. Serial sections from frozen
human samples dissected in the medullopapil-
lary region and whole rat kidney were used.
Autoradiograms were obtained by incubating
adjacent kidney sections with 1.5 nmol/L [3H]-
SR 121463 with (B and D; nonspecific binding)
and without (A, B; total binding) cold SR
121463 (1 mmol/L). Calibration bars corre-
spond to 2 mm.
markably stable steady state. The dissociation process nonpeptide compounds tested indicated that the homog-
enous population of sites labeled by [3H]-SR 121463 ex-of the receptor-ligand complex, using 1 mmol/L unlabeled
SR 121463, was slow and still partial after three hours, hibited the expected profile for human AVP V2 receptors
(Table 2), in good agreement with published values usingdemonstrating a tight association of [3H]-SR 121463 to
its binding sites. Both in CHO cells transfected with the [3H]-AVP as a ligand [47]: SR 121463 . SKF com-
pounds . AVP . OPC-31260 . dDAVP . SR 49059 »human V2 receptors and in renomedullary membranes
from native human kidney, which constitutively ex- d(CH2)5Tyr(Me)AVP . OT and OT analogues .
d(D-3Pal)AVP. A striking finding was that in CHO cellpresses AVP V2 receptors, [3H]-SR 121463 bound to a
single class of high-affinity binding sites (Kd 5 0.94 6 homogenates, [3H]-SR 121463 bound to a population of
AVP V2 sites that could not be displaced by AVP and0.34 nmol/L, Bmax 5 9876 6 317 fmol/mg protein—
approximately 500,000 sites/cell—and Kd 5 0.54 6 0.01 by other AVP V2-related peptides (that is, dDAVP, SKF
compounds). Similarly, saturation binding experimentsnmol/L, Bmax 5 223 6 19 fmol/mg protein, respectively).
The rank order of affinity of the reference peptide and performed simultaneously with [3H]-AVP and [3H]-SR
Serradeil-Le Gal et al: V2 receptors and [ 3H]-SR 1214631620
121463 in the same CHO preparation revealed a differ- 121463 may be a valuable tool for the localization of
extrarenal V2 receptors. Recent polymerase chain reac-ence in receptor density. A first hypothesis that [3H]-SR
121463 bound to sites unrelated to AVP V2 receptors tion studies have shown the presence of small amounts
of V2 mRNA in various animal and human tissues suchwas discarded since no specific binding could be detected
in untransfected CHO. An alternative explanation that as brain and lung tissues or cells [7, 11], and several in
vivo data suggest the presence of V2 or V2-like receptors[3H]-SR 121463 binds to a population of V2 receptors
with reduced affinity for agonists, as previously observed located in the vascular system, probably in endothelial
cells, responsible for vasodilation via a nitric oxide re-in various systems [48, 49], was rejected since neither
peptide agonists nor antagonists displaced this [3H]-SR lease pathway [55, 56]. In addition, the involvement of
AVP V2 extrarenal sites in clotting factor release has121463 AVP-resistant binding. It appears likely that the
[3H]-SR 121463 binding sites not displaced by AVP (and been clearly evidenced using the selective AVP V2 recep-
tor antagonist SR 121463 [14].other related V2 peptides) result from the sequestration
of a fraction of vesiculated V2 receptors in “right side In conclusion, this study reports the binding properties
of [3H]-SR 121463, the first radiolabeled selective non-in” vesicles that are available to small hydrophobic non-
peptide ligands, but not to more hydrophilic peptide peptide V2 receptor antagonist, described so far. The
potent affinity of this radioligand for both animal andanalogues. According to this hypothesis, more lipophylic
ligands, with a higher or lower affinity for V2 receptors, human AVP V2 receptors as well as its selectivity and
stability suggests that it is ideally suited for labeling V2totally displaced the bound [3H]-SR 121463. Thus, SR
49059, a V1a receptor antagonist exhibiting a moderate receptors in tissues expressing heterogenous populations
of AVP/OT receptors. This compound is also of interestaffinity for V2 receptors, was able to displace 100%
of [3H]-SR 121463 bound at high concentrations (1025 for further investigation of the role of AVP and V2 recep-
tors in physiological and pathological processes.mol/L), consistent with its V2 affinity (Ki 5 232 nmol/L).
In every case, the Hill coefficient about one is consistent
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APPENDIXcompounds such as SR 121463 and VPA 985, able to
Abbreviations used in this article are: AVP, arginine vasopressin;permeate membranes, did displace it. Other explanations
Bmax, maximum binding density; BSA, bovine serum albumin; CHO,involving different conformations of the V2 receptor, Chinese hamster ovary; dDAVP, 1-desamino-[D-Arg8]-vasopressin;
discriminated by peptide ligands, cannot be excluded. DMEM, Dulbecco’s modified Eagle’s medium; DMSO, dimethyl sulf-
oxide; EDTA, ethylediaminetetraacetic acid; k11, association rate con-In addition to its use as a selective ligand to measure
stant; k21, dissociation rate constant; Kd, dissociation constant; Ki, inhibi-V2 receptors, [3H]-SR 121463 can be used to localize V2 tion constant; kobs, observed rate constant; MEM, minimal essential
receptors in situ in animal and human tissue. The pattern medium; nH, Hill coefficient; OT, oxytocin; SCLC, small cell lung cancer;
SIADH, syndrome of inappropriate antidiuretic hormone secretion; SRof [3H]-SR 121463 labeling in the rat kidney was consis-
121463, 1-[4-(N-tert-butylcarbamoyl)-2-meth-oxybenzene sulfonyl]-5-tent with previous autoradiographic data [51], and with ethoxy-3-spiro-[4-(2-morpholinoethoxy-cyclohexane)] indoline-2-one,
the anatomical expression of mRNA encoding the V2 cis-isomer.
receptors as reported by Ostrowski, Young, and Knep-
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